Patents by Inventor Andrew A. Protter

Andrew A. Protter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Breast Cancer
    Publication number: 20210069154
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 11, 2021
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20190262315
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 29, 2019
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 10111861
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 30, 2018
    Assignees: Medivation Prostate Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of Breast Cancer
    Publication number: 20170087132
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 9517229
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 13, 2016
    Assignees: MEDIVATION PROSTATE THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Pyrido[4,3-b]indoles containing rigid moieties
    Patent number: 9458155
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: October 4, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC
    Inventors: David T. Hung, Andrew A. Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
    Publication number: 20150051218
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Inventors: David T. HUNG, Andrew A. PROTTER, Rajendra Parasmal JAIN, Sarvajit CHAKRAVARTY
  • TREATMENT OF BREAST CANCER
    Publication number: 20140296312
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 2, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Tetracyclic compounds
    Patent number: 8338408
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: December 25, 2012
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew A. Protter, Rajendra P. Jain, Sundeep Dugar, Sarvajit Chakravarty, Sergey O. Bachurin, Anatoly K. Ustinov, Bogdan K. Beznosko, Nadezhda Sergeevna Beznosko, legal representative, Elena F. Shevtsova, Vladimir V. Grigoriev
  • Tetracyclic compounds
    Publication number: 20090239854
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: October 27, 2008
    Publication date: September 24, 2009
    Inventors: David T. HUNG, Andrew A. PROTTER, Rajendra P. JAIN, Sundeep DUGAR, Sarvajit CHAKRAVARTY, Sergey O. BACHURIN, Anatoly K. USTINOV, Bogdan K. BEZNOSKO, Elena F. SHEVTSOVA, Vladimir V. GRIGORIEV, Nadezhda Sergeevna Beznosko
  • Glycosylated Probnp
    Publication number: 20080312152
    Abstract: The present invention is directed to glycosylated proBNP and pharmaceutical compositions thereof. The present invention also relates to novel assays for measuring the total natriuretic activity that is present in a clinical blood sample.
    Type: Application
    Filed: October 16, 2006
    Publication date: December 18, 2008
    Inventors: N. Stephen Pollitt, Rodney A. Jue, Andrew A. Protter, Jessica O"Rear, Andrew Guzzetta, Ute Schellenberger
  • Oxidized Human Bnp
    Publication number: 20080227713
    Abstract: The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP).
    Type: Application
    Filed: October 3, 2006
    Publication date: September 18, 2008
    Inventor: Andrew A. Protter
  • METHODS OF PROMOTING OSTEOGENESIS
    Publication number: 20080108658
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 8, 2008
    Inventors: Andrew Protter, David Liu, Patrick O'Connor
  • Treatment of pain by inhibition of p38 map kinase
    Publication number: 20080039461
    Abstract: The present invention relates to methods for the prevention or treatment of pain by the inhibition of p38 MAP kinase.
    Type: Application
    Filed: December 28, 2006
    Publication date: February 14, 2008
    Inventors: Andrew Protter, Camilla Svensson, Tony Yaksh, Barbara Cordell, Sundeep Dugar
  • Methods of promoting osteogenesis
    Patent number: 7268139
    Abstract: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: September 11, 2007
    Assignee: Scios, Inc.
    Inventors: Andrew A. Protter, David Y. Liu, Patrick O'Connor
  • Recombinant fibroblast growth factor analogs
    Patent number: 7186526
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 6, 2007
    Assignee: Scios, Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
    Publication number: 20060058296
    Abstract: The present invention provides a method to treat osteolytic lesions associated with multiple myeloma by the administration of one or more p38 MAP kinase inhibitors.
    Type: Application
    Filed: August 19, 2005
    Publication date: March 16, 2006
    Applicant: Scios, Inc.
    Inventors: Linda Higgins, Andrew Protter
  • Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
    Publication number: 20060052390
    Abstract: The present invention provides a method to treat multiple myeloma by the co-administration of one or more p38 MAP kinase inhibitors with one or more proteosome inhibitors.
    Type: Application
    Filed: August 19, 2005
    Publication date: March 9, 2006
    Applicant: Scios, Inc.
    Inventors: George Schreiner, Andrew Protter, Linda Higgins
  • Recombinant fibroblast growth factor analogs
    Publication number: 20050227329
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: June 13, 2005
    Publication date: October 13, 2005
    Inventors: John Fiddes, Judith Abraham, Andrew Protter
  • Treatment of obesity and associated conditions with TGF-beta inhibitors
    Publication number: 20040192583
    Abstract: The invention concerns the treatment obesity and associated conditions with TGF-&bgr; inhibitors. More specifically, the invention concerns the use of TGF-&bgr; inhibitors in the treatment of obesity, type 2 diabetes, and pathologic conditions associated with obesity or type 2 diabetes.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 30, 2004
    Inventors: Satyanarayana Medicherla, Andrew A. Protter, George F. Schreiner